TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER).
Travasol 2.75% in Dextrose 10% provides essential amino acids and caloric support via dextrose. Amino acids serve as substrates for protein synthesis and nitrogen balance, while dextrose provides glucose for energy metabolism. The combination is used for parenteral nutrition to maintain or restore positive nitrogen balance in patients unable to tolerate enteral nutrition.
| Metabolism | Amino acids undergo deamination and transamination primarily in the liver, with nitrogen excreted as urea. Dextrose is metabolized via glycolysis and the citric acid cycle to produce ATP. |
| Excretion | TRAVASOL 2.75% IN DEXTROSE 10% is a combination of amino acids and dextrose. The amino acids are primarily metabolized and the nitrogen is excreted as urea in urine (renal, >90%). Dextrose is metabolized to CO2 and water; negligible biliary/fecal excretion. |
| Half-life | Not applicable as a single entity. Components are endogenous substances. Dextrose has a half-life of minutes due to rapid insulin-mediated uptake. Amino acids have variable half-lives (minutes to hours) depending on individual amino acid and metabolic state. |
| Protein binding | Amino acids: minimal protein binding (<10%, primarily albumin). Dextrose: no significant protein binding. |
| Volume of Distribution | Amino acids distribute similarly to endogenous pools (Vd ~0.5 L/kg); dextrose distributes in extracellular fluid (Vd ~0.2 L/kg). As a combined product, effective Vd is approximately 0.2-0.5 L/kg. |
| Bioavailability | Intravenous: 100% bioavailability. Not administered orally; enteral bioavailability is not applicable. |
| Onset of Action | Intravenous: Immediate onset of caloric (dextrose) and nitrogen (amino acids) provision upon infusion. Clinical effects on metabolic support begin within minutes. |
| Duration of Action | Duration depends on infusion rate and metabolic demands. Continuous infusion provides sustained caloric and nitrogen support. After discontinuation, metabolic effects persist for hours as substrates are utilized. |
Intravenous infusion. 1000 mL to 3000 mL per day, typically infused at 1.2-1.5 g amino acids/kg/day; adjust based on metabolic needs and fluid status.
| Dosage form | INJECTABLE |
| Renal impairment | eGFR <30 mL/min/1.73m2: Administer with caution, reduce amino acid dose to 0.5-0.8 g/kg/day. Monitor electrolytes and acid-base status. Not recommended for patients on dialysis without specialized amino acid formulations. |
| Liver impairment | Child-Pugh Class B or C: Avoid or use with extreme caution due to risk of hepatic encephalopathy. Reduce dose to 0.3-0.6 g amino acids/kg/day if necessary. |
| Pediatric use | Weight-based: 2-3 g amino acids/kg/day for term infants; 2.5-3.5 g/kg/day for preterm infants. Adjust fluid and dextrose accordingly. Maximum infusion rate 0.1-0.15 g amino acids/kg/hour. |
| Geriatric use | Start at lower end of adult dosing (1000-2000 mL/day) due to increased risk of fluid overload and electrolyte imbalances. Monitor renal function and adjust dose accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER).
| Breastfeeding | Excretion into breast milk is negligible as amino acids and dextrose are normal milk constituents. M/P ratio is not established. Considered compatible with breastfeeding, but ensure maternal nutritional status is adequate. |
| Teratogenic Risk | TRAVASOL 2.75% IN DEXTROSE 10% is a combination of amino acids and dextrose used for parenteral nutrition. No specific teratogenic effects are reported for this combination. However, parenteral nutrition in pregnancy may be necessary if oral intake is inadequate. Fetal risks are primarily related to maternal malnutrition or underlying conditions rather than direct drug effects. Use during all trimesters is considered low risk, but careful monitoring for metabolic complications is advised. |
■ FDA Black Box Warning
None. However, solutions containing dextrose may cause hyperglycemia; use with caution in patients with diabetes or glucose intolerance.
| Serious Effects |
["Severe metabolic acidosis","Severe hyperglycemia or hyperosmolar state","Hypersensitivity to any component","Azotemia or anuria (risk of urea accumulation)","Inborn errors of amino acid metabolism"]
| Precautions | ["Monitor for signs of hyperglycemia, fluid overload, electrolyte imbalances, and metabolic acidosis","Risk of venous thrombosis or phlebitis at infusion site (peripheral administration)","Use with caution in patients with renal impairment, hepatic insufficiency, or fluid/electrolyte disturbances","Do not administer subcutaneously or intramuscularly"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose, electrolytes, acid-base balance, and liver function tests. Assess for signs of infection or phlebitis. Fetal well-being monitoring with ultrasound and non-stress test as clinically indicated. |
| Fertility Effects | No known effects on fertility. Parenteral nutrition corrects malnutrition which may improve fertility in undernourished women. |